GLYCOMIMETICS WKN: A1W8HZ ISIN: US38000Q1022 Kürzel: GKO Forum: Aktien Thema: Hauptdiskussion

Was geht nun ab?

https://www.businesswire.com/news/home/20240327799407/en/GlycoMimetics-Reports-Highlights-and-Financial-Results-for-Fourth-Quarter-and-Full-Year-2023

🤷🏻‍♂️

Was los hier?

https://ir.glycomimetics.com/news-releases/news-release-details/glycomimetics-reports-highlights-and-financial-results-first-1

https://www.businesswire.com/news/home/20230329005358/en/GlycoMimetics-Reports-Highlights-and-Financial-Results-for-Fourth-Quarter-and-Year-end-2022

https://ir.glycomimetics.com/node/11691/html ... GlycoMimetics, Inc., a Delaware corporation (the “Company”), currently maintains an account at Silicon Valley Bank (“SVB”) holding cash deposits of approximately $2 million, which amount the Company considers to be immaterial to its liquidity. ...

Es wurde empfohlen die Studie weiterzuführen, das ist doch gut, oder?

Nein, sie haben Aktien verkauft

Ok, zwei negative Nachrichten 1.Die Studie für das neue Medikament dauert länger als erwartet. 2. Sie haben neue Aktien auf den Markt geschmissen, was Automatisch den Wert der bisherigen reduzieren. Lest ihr das auch so?

https://www.tipranks.com/news/glycomimetics-plunges-on-new-stock-offering?utm_source=webullapp.com&utm_medium=referral

Ist das bitter heute, kann kein Grund finden.

Nur, dass sie halt Aktien verkauft haben, dadurch fällt der Preis. Das wäre aber etwas harmloses.

Ich lese da nicht schlechtes, vielleicht hab ich auch Tomaten auf den Augen

Was das für den Aktienkurs bedeutet keine Ahnung. Clinical-stage biotech GlycoMimetics (NASDAQ:GLYC) lost ~40% pre-market Wednesday after announcing that the company sold ~11.8M shares of its common stock in an “at-the-market” offering from the start of Q4 2022. The company said the capital raise would extend its cash runway into Q4 2024. The share sale has added $32.9M in net proceeds, which GlycoMimetics (GLYC) expects to use for further studies and preparations to seek marketing approval and potential commercialization of its leukemia therapy uproleselan. Additionally, the company announced that an independent panel recommended that its pivotal Phase 3 study for uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML) be continued as initially designed. The decision follows a recently-added interim analysis performed ahead of the originally-planned final overall survival analysis expected in H1 2024. In November, GlycoMimetics (GLYC) estimated final survival events trigger to occur around year-end 2023.

Das sieht aber gar nicht gut aus ☹️